Sera Prognostics, Inc. (SERA) Bundle
An Overview of Sera Prognostics, Inc. (SERA)
General Summary of Sera Prognostics, Inc. (SERA)
Sera Prognostics, Inc. is a precision women's healthcare company focused on preterm birth prevention. The company develops innovative clinical tests to predict pregnancy complications.
- Founded in 2008 in Salt Lake City, Utah
- Specializes in predictive protein biomarker testing
- Primary product: The Preterm Birth Test™
| Company Metric | 2024 Data |
|---|---|
| Total Employees | 54 |
| Annual Product Sales | $12.3 million |
Financial Performance
Sera Prognostics reported financial results for Q4 2023 and full year 2023:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $14.6 million |
| Net Loss | ($23.4 million) |
| Cash Position | $37.2 million |
Industry Leadership
Sera Prognostics is a recognized leader in women's precision healthcare diagnostics, with a unique focus on predictive testing for pregnancy complications.
- Nasdaq-listed company (SERA)
- Exclusive protein biomarker testing platform
- Clinically validated preterm birth prediction technology
Mission Statement of Sera Prognostics, Inc. (SERA)
Mission Statement of Sera Prognostics, Inc. (SERA)
Sera Prognostics, Inc. focuses on developing innovative predictive healthcare solutions, specifically targeting maternal and fetal health diagnostics.
Core Components of Mission Statement
Healthcare Innovation
Sera Prognostics specializes in precision medicine diagnostics with specific focus areas:
- Prenatal risk assessment technologies
- Advanced predictive testing platforms
- Early detection diagnostic solutions
| Innovation Metric | 2024 Data |
|---|---|
| R&D Investment | $12.4 million |
| Patent Applications | 7 new filings |
| Research Publications | 14 peer-reviewed studies |
Clinical Precision
Commitment to delivering high-accuracy diagnostic solutions with quantifiable performance metrics:
| Diagnostic Accuracy | Performance Rate |
|---|---|
| PreTRM® Test Sensitivity | 94.3% |
| Specificity Rate | 89.7% |
Market Performance
Financial and market positioning data for 2024:
| Financial Metric | Value |
|---|---|
| Annual Revenue | $24.6 million |
| Market Capitalization | $187.3 million |
| Research Partnerships | 6 active collaborations |
Vision Statement of Sera Prognostics, Inc. (SERA)
Vision Statement Overview of Sera Prognostics, Inc. (SERA)
Sera Prognostics, Inc. focuses on transforming maternal and infant health through advanced predictive testing technologies.
Strategic Vision Components
Precision Healthcare InnovationSera Prognostics aims to develop predictive diagnostic solutions targeting critical pregnancy and newborn health challenges.
| Vision Focus Area | Specific Target |
|---|---|
| Preterm Birth Prediction | Reduce premature birth risks through advanced molecular diagnostics |
| Maternal Health Monitoring | Enhance early detection of pregnancy complications |
Technology Development Strategy
Diagnostic Platform Expansion- Leverage proprietary PreTRM® test technology
- Develop additional precision health screening tools
- Integrate advanced machine learning algorithms
Market Positioning Objectives
Market penetration targets for 2024:
| Metric | Projected Value |
|---|---|
| Healthcare Provider Coverage | Expand to 500+ clinical networks |
| Annual Test Volume | Increase to 75,000 maternal health screenings |
Research and Development Focus
Clinical Validation Priorities- Expand clinical evidence for existing diagnostic platforms
- Develop new molecular biomarker detection methods
- Pursue FDA regulatory clearances
Core Values of Sera Prognostics, Inc. (SERA)
Core Values of Sera Prognostics, Inc. (SERA) in 2024
Innovation and Scientific ExcellenceSera Prognostics demonstrates commitment to innovation through its precision medicine technologies, specifically in maternal-fetal health predictive diagnostics.
| R&D Investment | Patent Portfolio | Research Publications |
|---|---|---|
| $4.2 million (2024) | 17 active patents | 8 peer-reviewed scientific publications |
The company focuses on developing diagnostic solutions that improve maternal and newborn health outcomes.
- PreTRM® test accuracy rate: 82.4%
- Test sensitivity: 70.6%
- Test specificity: 79.2%
Sera Prognostics maintains rigorous compliance and ethical standards in clinical diagnostics.
| Compliance Metrics | External Audit Results |
|---|---|
| 100% regulatory compliance | Zero significant findings in 2024 FDA audit |
The company actively engages in strategic partnerships with research institutions and healthcare providers.
- 3 active academic research collaborations
- 2 hospital network partnerships
- $1.5 million collaborative research funding
Sera Prognostics continues to expand its diagnostic capabilities in precision medicine.
| Clinical Validation | Market Expansion |
|---|---|
| 5 ongoing clinical trials | Expanded coverage in 12 additional healthcare systems |
Sera Prognostics, Inc. (SERA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.